Olaparib in gBRCA+ Breast Cancer; ‘Clearly Practice Changing’

Via Peters

Adjuvant olaparib (Lynparza) significantly improves overall survival (OS), compared with placebo, for patients with high-risk, early-stage, HER2-negative, germline BRCA-mutated breast cancer, according to the latest results from the pivotal phase 3 OlympiA trial. Olaparib was recently approved for this indication, as reported by Medscape Medical News; the approval was based […]